These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 21629218)

  • 1. Targeting 5α-reductase for prostate cancer prevention and treatment.
    Nacusi LP; Tindall DJ
    Nat Rev Urol; 2011 May; 8(7):378-84. PubMed ID: 21629218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
    Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
    Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
    Tindall DJ; Rittmaster RS
    J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
    Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J
    J Androl; 2003; 24(5):681-7. PubMed ID: 12954658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5α-reductase type 3 enzyme in benign and malignant prostate.
    Titus MA; Li Y; Kozyreva OG; Maher V; Godoy A; Smith GJ; Mohler JL
    Prostate; 2014 Feb; 74(3):235-49. PubMed ID: 24150795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone.
    Dadras SS; Cai X; Abasolo I; Wang Z
    Gene Expr; 2001; 9(4-5):183-94. PubMed ID: 11444528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders.
    Paba S; Frau R; Godar SC; Devoto P; Marrosu F; Bortolato M
    Curr Pharm Des; 2011; 17(2):151-67. PubMed ID: 21361868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
    Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
    Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK; Ross M; Tate R; Chisholm GD
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5alpha-reductase activity in the prostate.
    Steers WD
    Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.
    Azzouni F; Mohler J
    Urology; 2012 Jun; 79(6):1197-205. PubMed ID: 22446342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of 5α-reductase inhibitors in benign prostatic diseases.
    Azzouni F; Mohler J
    Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):222-30. PubMed ID: 22333687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific.
    Chhipa RR; Halim D; Cheng J; Zhang HY; Mohler JL; Ip C; Wu Y
    Prostate; 2013 Oct; 73(14):1483-94. PubMed ID: 23813737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention.
    Li J; Ding Z; Wang Z; Lu JF; Maity SN; Navone NM; Logothetis CJ; Mills GB; Kim J
    PLoS One; 2011; 6(12):e28840. PubMed ID: 22194926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
    Gupta S; Wang Y; Ramos-Garcia R; Shevrin D; Nelson JB; Wang Z
    Prostate; 2010 Oct; 70(14):1575-85. PubMed ID: 20564326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.
    Mohler JL; Titus MA; Wilson EM
    Clin Cancer Res; 2011 Sep; 17(18):5844-9. PubMed ID: 21705451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.
    Austin DC; Strand DW; Love HL; Franco OE; Grabowska MM; Miller NL; Hameed O; Clark PE; Matusik RJ; Jin RJ; Hayward SW
    Prostate; 2016 Aug; 76(11):1004-18. PubMed ID: 27197599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.
    Li Z; Alyamani M; Li J; Rogacki K; Abazeed M; Upadhyay SK; Balk SP; Taplin ME; Auchus RJ; Sharifi N
    Nature; 2016 May; 533(7604):547-51. PubMed ID: 27225130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.